EOCN
Galmed Pharmaceuticals Ltd.
There isn't enough reported data to score EOCN yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
EOCN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
EOCN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
EOCN PE Valuation
EOCN has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
EOCN Forward outlook
There aren't enough analyst estimates for EOCN to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
EOCN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2023 | -$240.00 | +$782.40 |
| Q4 2022 | -$1,022.40 | +$878.40 |
| Q4 2021 | -$1,900.80 | +$50.81 |
| Q4 2020 | -$1,951.61 | -$555.87 |
| Q2 2020 | -$1,661.92 | -$768.77 |
| Q4 2019 | -$1,395.74 | -$535.77 |
| Q2 2019 | -$893.15 | +$339.67 |
| Q4 2018 | -$859.97 | +$575.82 |
EOCN is still losing money, but far less than before: $240.00 per share over the past year, against $2,146.20 at its worst in late 2016.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over EOCN in the latest year-over-year earnings comparison.
EOCN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2018 | $1.5M | +174% |
| Q2 2018 | $538K | 0% |
| Q4 2017 | $547K | +17% |
LLY has the edge over EOCN in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2018 | -306% | +3302 points |
| Q2 2018 | -965% | N/A |
| Q4 2017 | -1178% | N/A |
| Q2 2017 | -1088% | N/A |
| Q4 2016 | -3607% | N/A |
EOCN's operating margin was −306% last quarter, up 3301 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over EOCN in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
EOCN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2022 | -$18.5M | +$14.4M |
| Q2 2022 | -$11.4M | +$5.6M |
| Q4 2021 | -$32.9M | -$19.4M |
| Q2 2021 | -$16.9M | -$4.1M |
| Q4 2020 | -$13.5M | -$5.5M |
| Q2 2020 | -$12.8M | -$5.8M |
| Q4 2019 | -$7.9M | -$3.7M |
| Q2 2019 | -$7M | -$2.1M |
EOCN has burned cash in almost every quarter: −$80M over the past year, against −$41M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
EOCN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +65% | +350K shares |
| 1 year | +1351% | +828K shares |
| 3 years | +5951% | +874K shares |
| 5 years | +11429% | +881K shares |
EOCN has 888,762 diluted shares, up 1351% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over EOCN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
EOCN Net Leverage
EOCN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
EOCN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 16.2 | Oversold |
EOCN's weekly RSI is 31 (neutral) and its Stochastic is 16 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
EOCN PE vs Healthcare Sector
EOCN has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
EOCN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.11 | 23% below |
| 20 week MA | $3.80 | 37% below |
| 50 week MA | $4.86 | 51% below |
| 100 week MA | $9.57 | 75% below |
| 200 week MA | $94.9 | 97% below |
EOCN is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over EOCN on trend strength, trading above more of its moving averages.
EOCN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8,222.4 | $5,184.0 | -37% |
| 2021 | $5,184.0 | $2,923.2 | -44% |
| 2022 | $2,923.2 | $774.3 | -74% |
| 2023 | $774.3 | $43.7 | -94% |
| 2024 | $43.7 | $25.0 | -43% |
| 2025 | $25.0 | $6.92 | -72% |
| 2026 YTD | $6.92 | $2.39 | -65% |
EOCN has finished every year since 2020 lower, and it's down 65% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over EOCN on returns for 2026, with the stronger performance.